The first targetedtreatment for HER2+ breast cancer to receive FDA approval was thehumanized monoclonal antibody trastuzumab, which inhibits the growthof cultured HER2+ breast cancer cells by binding to the extracellulardomain of HER2.144 Trastuzumab was combinedwith DOTA and radiolabeled with copper-64. The gene discussed is ERBB2; the disease is breast cancer.